Edition:
United Kingdom

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

5.45USD
25 Apr 2018
Change (% chg)

$-0.05 (-0.91%)
Prev Close
$5.50
Open
$5.50
Day's High
$5.50
Day's Low
$5.45
Volume
384
Avg. Vol
38,072
52-wk High
$7.20
52-wk Low
$2.25

Chart for

About

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy... (more)

Overall

Beta: 5.35
Market Cap(Mil.): $249.02
Shares Outstanding(Mil.): 42.21
Dividend: --
Yield (%): --

Financials

  VTL.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.37 -- --
ROI: -63.60 1.58 14.38
ROE: -63.63 2.41 16.07

BRIEF-Vital Therapies Announces VTL-308 Reaches Enrollment Target Of 150 Subjects

* VITAL THERAPIES ANNOUNCES VTL-308 REACHES ENROLLMENT TARGET OF 150 SUBJECTS

22 Mar 2018

BRIEF-Vital Therapies Announces Q4 Loss Per Share $0.35

* VITAL THERAPIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

13 Mar 2018

BRIEF-Vital Therapies Appoints Russell J. Cox As Chief Executive Officer And Board Member

* VITAL THERAPIES APPOINTS RUSSELL J. COX AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER EFFECTIVE JANUARY 3, 2018

04 Dec 2017

BRIEF-Vital Therapies reports Q3 loss per share $0.30

* Vital therapies announces third quarter 2017 financial results

25 Oct 2017

Earnings vs. Estimates